Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Cash from Financing Activities (2022 - 2025)

Taysha Gene Therapies (TSHA) has disclosed Cash from Financing Activities for 4 consecutive years, with $49.6 million as the latest value for Q4 2025.

  • Quarterly Cash from Financing Activities rose 13981.23% to $49.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $274.6 million through Dec 2025, up 258.08% year-over-year, with the annual reading at $274.6 million for FY2025, 258.08% up from the prior year.
  • Cash from Financing Activities hit $49.6 million in Q4 2025 for Taysha Gene Therapies, up from $8.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $216.3 million in Q2 2025 to a low of -$4.2 million in Q4 2023.
  • Historically, Cash from Financing Activities has averaged $33.7 million across 4 years, with a median of $3.5 million in 2023.
  • Biggest YoY gain for Cash from Financing Activities was 136637.86% in 2023; the steepest drop was 245.79% in 2023.
  • Year by year, Cash from Financing Activities stood at $41.2 million in 2022, then plummeted by 110.3% to -$4.2 million in 2023, then soared by 91.6% to -$357000.0 in 2024, then skyrocketed by 13981.23% to $49.6 million in 2025.
  • Business Quant data shows Cash from Financing Activities for TSHA at $49.6 million in Q4 2025, $8.8 million in Q3 2025, and $216.3 million in Q2 2025.